NanoVibronix Receives Reimbursement Approval from U.S. Centers for Medicare & Medicaid Services (CMS) for PainShield Enables Providers to Prescribe PainShield to Help Individuals Manage Pain at Home, Avoiding Unnecessary

NanoVibronix Receives Reimbursement Approval

from U.S. Centers for Medicare & Medicaid Services (CMS) for PainShield

Enables Providers to Prescribe

PainShield to Help Individuals Manage Pain at Home, Avoiding Unnecessary Doctor Visits and Hospitalization During COVID-Related

Stay-At-Home Proclamations

ELMSFORD, N.Y., April

1, 2020 (GLOBE NEWSWIRE) -- NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company that produces the PainShield

Surface Acoustic Wave (SAW) Portable Ultra Sonic therapeutic device, today announced that the U.S. Centers for Medicare and Medicaid

Services (CMS) has approved its PainShield for reimbursement for Medicare beneficiaries on a national basis effective January

"PainShield provides an effective alternative

to pharmaceuticals for pain management and can be used in a variety of settings including the safety of a patient's home,

which has become increasingly important in light of the coronavirus (COVID-19) pandemic," said Brian Murphy, CEO of NanoVibronix.

"Receiving CMS approval increases the number of providers who may prescribe PainShield as a means for patients, particularly

Medicare beneficiaries who may be at a higher risk of infection, to manage their pain while maintaining safe distances and reducing

contact in clinical settings. Obtaining this approval strengthens our opportunities to secure private label partners in the United

was notified on March 30, 2020 that its Medicare Enrollment Application was approved, and it is now an approved Medicare Supplier

for DME through the National Supplier Clearinghouse, Palmetto-GBA as well as Noridian Administrative Services, LLC, the two Medicare

Administrative Contractors that handle DME reimbursement nationwide.

PainShield is now available for Medicare reimbursement

on a national level under new HCPCS (Healthcare Common Procedure Coding System) code K1004.

PainShield is an ultrasound device, consisting

of a reusable driver unit and a disposable patch, which contains a proprietary therapeutic transducer. PainShield delivers a localized

ultrasound effect to treat pain and induce soft tissue healing in a targeted area, while keeping the level of ultrasound energy

at a safe and consistent level. Its range of applications includes acute and chronic pain resolution through its many mechanisms

of action. PainShield can be used by patients at home or work or in a clinical setting and can be used even while the patient is

sleeping. Patient benefits include ease of application and use, faster recovery time, high compliance, and increased safety and

efficacy over existing devices that rely on higher-frequency ultrasound.

NanoVibronix Inc. (NASDAQ:

NAOV) is a medical device company headquartered in Elmsford, New York, with research and development in Nesher, Israel, which is

focused on developing medical devices utilizing its proprietary and patented low intensity surface acoustic wave (SAW) technology.

This technology allows for the creation of low-frequency ultrasound waves that can be utilized for a variety of medical applications,

including the disruption of biofilms and bacteria colonization, as well as providing pain relief. The devices can be administered

at home without the assistance of medical professionals. The Company's primary products include PainShield , UroShield

and WoundShield . Additional information about the Company is available at: www.nanovibronix.com.

Forward-looking Statements

contains "forward-looking statements." Such statements may be preceded by the words "intends," "may,"

"will," "plans," "expects," "anticipates," "projects," "predicts,"

"estimates," "aims," "believes," "hopes," "potential" or similar words.

Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various

known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified

and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such

risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the geographic, social and economic

impact of COVID-19 on the Company's ability to conduct its business and raise capital in the future when needed, (ii) market

acceptance of our existing and new products or lengthy product delays in key markets; (iii) negative or unreliable clinical trial

results (iv) an inability to secure regulatory approvals for the sale of our products, (v) intense competition in the medical device

industry from much larger, multinational companies, (vi) product liability claims, (vii) product malfunctions, (viii) our limited

manufacturing capabilities and reliance on subcontractors for assistance, (ix) insufficient or inadequate reimbursement by governmental

and other third party payers for our products, ix) our efforts to successfully obtain and maintain intellectual property protection

covering our products, which may not be successful, (xi) legislative or regulatory reform of the healthcare system in both the

U.S. and foreign jurisdictions, (xii) our reliance on single suppliers for certain product components, (xiii) the fact that we

will need to raise additional capital to meet our business requirements in the future and that such capital may not be available,

or may be costly, dilutive or difficult to obtain and (xiv) the fact that we conduct business in multiple foreign jurisdictions,

exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance

with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and

the risk factors that may affect the realization of forward looking statements is set forth in the Company's filings with

the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports

on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov.

The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future

events or otherwise.

Brett Maas, Managing Principal, Hayden IR, LLC

SOURCE: NanoVibronix, Inc.